Study T-cell therapy for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a custom immune-cell treatment made to target a marker (GPC3) found on some liver cancers. It’s for adults with advanced HCC whose cancer has worsened after standard treatment or who couldn’t tolerate it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed advanced HCC (unresectable, recurring, and/or metastatic).
- Your tumor must test positive for GPC3 on tissue testing; the exact cutoff depends on the study phase.
- You’ve already had at least one standard (first-line) medicine for HCC and your cancer progressed or you couldn’t tolerate it.
- Your overall health score is good (ECOG 0 to 1) and you’re expected to live at least 4 months.
- Your liver function is fairly well preserved (Child-Pugh A6 or better) and your organs are strong enough for study treatment.
- You must have at least one measurable tumor spot on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests an immune-cell treatment (ET140203 T cells) in children and teens with certain liver cancers that have come back or did not respond to standard treatment. It aims to see whether these T cells can shrink tumors and is mainly focused on safety and early effectiveness.
This trial studies an experimental cell therapy that uses your own immune cells collected from your tumor to fight the cancer. It aims to see if this approach is safe and effective for advanced liver cancer that has progressed after standard treatments.
This Phase 1 study tests a personalized immune-cell treatment (CAR T cells) for advanced liver cancer that has the GPC3 protein. It aims to see whether these engineered cells can find and kill cancer cells safely and help shrink the cancer.
This early-phase study tests modified immune T cells (CAR T cells) to treat hepatocellular carcinoma (HCC), a type of liver cancer, when the tumor shows a marker called GPC3. It may help shrink tumors or slow cancer growth, especially after other treatments have stopped working.
This trial tests a special type of immune cell therapy (called HBV-TCR T cells) that is designed to attack liver cancer cells that carry the hepatitis B virus. It may be given alone or combined with a pill called lenvatinib to see if it can shrink tumors and help people with advanced liver cancer.
This trial tests a custom immune-cell treatment (CAR-T) that targets a marker called GPC3 in people with advanced hepatocellular carcinoma (a type of liver cancer). It’s for cases where standard treatments have not worked well, and the goal is to shrink tumors and improve outcomes.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.